| 2013 |
- Kitajima Plant completed in Tokushima Prefecture
- Agreement signed on transfer of Astellas' fermentation research-related assets to Taiho
|
|---|
| 2014 |
- Name of US-based subsidiary changed from Taiho Pharma U.S.A., Inc. to Taiho Oncology, Inc.
|
|---|
| 2015 |
- Approval obtained from the U.S. FDA for the anticancer drug LONSURF (TAS-102) as a treatment for refractory metastatic colorectal cancer
- Marketing approval for TS-ONE obtained in Myanmar
|
|---|
| 2016 |
- Tiovita 3000 launched in Hong Kong
- Approval for LONSURF obtained in Europe
- TAIHO VENTURES, LLC established in California in the U.S.
- CTM Building (clinical trial materials manufacturing facility) completed at the Kitajima Plant
- TAIHO PHARMA CANADA, INC. established in Canada
|
|---|
| 2017 |
- Taiho Pharmaceutical Concludes Option and License Agreement with Arcus Biosciences
- Taiho Pharmaceutical Acquires Marketing Approval for LONSURF in Hong Kong and Taiwan
- Taiho Pharmaceutical Signs a Co-promotion Agreement with Janssen Pharmaceutical K.K. for Guselkumab, a Human Anti-interleukin (IL)-23 Monoclonal Antibody, in Japan
|
|---|
| 2018 |
- HP building (Highly Potent Pharmaceutical Ingredients) completed at Saitama Site
- Approval for LONSURF obtained in Canada
|
|---|
| 2019 |
- Taiho Innovations, LLC, established in Japan
- Participated in READYFOR SDGs, using crowd funding to support organizations addressing issues in the field of oncology
- Taiho Pharmaceutical greenhouse gas emissions reduction Targets earn Science Based Targets (SBT) initiative certification
- Awarded gold prize at the Cancer Ally Awards 2019
|
|---|
| 2022 |
- Taiho Pharmaceutical and Cullinan Oncology announce strategic collaboration to jointly develop and commercialize CLN-081/TAS6417 and Taiho’s acquisition of Cullinan Pearl
- U.S. FDA approves FGFR Inhibitor, futibatinib for the treatment of previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma
|
|---|
| 2023 |
- Approval of LYTGOBI for cholangiocarcinoma obtained in Europe (conditional marketing authorization)
- Approval for the combination therapy of LONSURF and bevacizumab for colorectal cancer obtained in Europe and the United States
- Awarded ”Gold” prize (5 years in a row) and “Best Practice” at the Cancer Ally Awards 2023
|
|---|
| 2024 |
- Entered into a licensing agreement with Haihe Biopharma for gumarontinib(SCC244), a treatment for non-small cell lung cancer
- Established ARIRGE Co., Ltd., a new company to address social issues related to cancer
- Otsuka Pharmaceutical and Taiho Pharmaceutical Commence Material Recycling of Waste PTP Used in Pharmaceutical Packaging
- Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia
|
|---|
| 2025 |
- Solar Power Generation Facility Launched at Taiho Pharmaceutical’s Kitajima Plant to Accelerate Carbon Neutrality Initiatives
- Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech
|
|---|
